Cargando…

Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women

IMPORTANCE: Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic cancer. Its early detection is advisable because 20% of women have advanced disease at the time of diagnosis. OBJECTIVE: To clinically validate a metabolomics-based classification algorithm as a screening test for EC....

Descripción completa

Detalles Bibliográficos
Autores principales: Troisi, Jacopo, Raffone, Antonio, Travaglino, Antonio, Belli, Gaetano, Belli, Carmen, Anand, Santosh, Giugliano, Luigi, Cavallo, Pierpaolo, Scala, Giovanni, Symes, Steven, Richards, Sean, Adair, David, Fasano, Alessio, Bottigliero, Vincenzo, Guida, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522698/
https://www.ncbi.nlm.nih.gov/pubmed/32986110
http://dx.doi.org/10.1001/jamanetworkopen.2020.18327
_version_ 1783588240910974976
author Troisi, Jacopo
Raffone, Antonio
Travaglino, Antonio
Belli, Gaetano
Belli, Carmen
Anand, Santosh
Giugliano, Luigi
Cavallo, Pierpaolo
Scala, Giovanni
Symes, Steven
Richards, Sean
Adair, David
Fasano, Alessio
Bottigliero, Vincenzo
Guida, Maurizio
author_facet Troisi, Jacopo
Raffone, Antonio
Travaglino, Antonio
Belli, Gaetano
Belli, Carmen
Anand, Santosh
Giugliano, Luigi
Cavallo, Pierpaolo
Scala, Giovanni
Symes, Steven
Richards, Sean
Adair, David
Fasano, Alessio
Bottigliero, Vincenzo
Guida, Maurizio
author_sort Troisi, Jacopo
collection PubMed
description IMPORTANCE: Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic cancer. Its early detection is advisable because 20% of women have advanced disease at the time of diagnosis. OBJECTIVE: To clinically validate a metabolomics-based classification algorithm as a screening test for EC. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study enrolled 2 cohorts. A multicenter prospective cohort, with 50 cases (postmenopausal women with EC; International Federation of Gynecology and Obstetrics stage I-III and grade G1-G3) and 70 controls (no EC but matched on age, years from menopause, tobacco use, and comorbidities), was used to train multiple classification models. The accuracy of each trained model was then used as a statistical weight to produce an ensemble machine learning algorithm for testing, which was validated with a subsequent prospective cohort of 1430 postmenopausal women. The study was conducted at the San Giovanni di Dio e Ruggi d’Aragona University Hospital of Salerno (Italy) and Lega Italiana per la Lotta contro i Tumori clinic in Avellino (Italy). Data collection was conducted from January 2018 to February 2019, and analysis was conducted from January to March 2019. MAIN OUTCOMES AND MEASURES: The presence or absence of EC based on evaluation of the blood metabolome. Metabolites were extracted from dried blood samples from all participants and analyzed by gas chromatography–mass spectrometry. A confusion matrix was used to summarize test results. Performance indices included sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and accuracy. Confirmation or exclusion of EC in women with a positive test result was by means of hysteroscopy. Participants with negative results were followed up 1 year after enrollment to investigate the appearance of EC signs. RESULTS: The study population consisted of 1550 postmenopausal women. The mean (SD) age was 68.2 (11.7) years for participants with no EC in the training cohort, 69.4 (13.8) years for women with EC in the training cohort, and 59.7 (7.7) years for women in the validation cohort. Application of the ensemble machine learning to the validation cohort resulted in 16 true-positives, 2 false-positives, and 0 false-negatives, and it correctly classified more than 99% of samples. Disease prevalence was 1.12% (16 of 1430). CONCLUSIONS AND RELEVANCE: In this study, dried blood metabolomic profile was used to assess the presence or absence of EC in postmenopausal women not receiving hormonal therapy with greater than 99% accuracy.
format Online
Article
Text
id pubmed-7522698
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-75226982020-10-05 Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women Troisi, Jacopo Raffone, Antonio Travaglino, Antonio Belli, Gaetano Belli, Carmen Anand, Santosh Giugliano, Luigi Cavallo, Pierpaolo Scala, Giovanni Symes, Steven Richards, Sean Adair, David Fasano, Alessio Bottigliero, Vincenzo Guida, Maurizio JAMA Netw Open Original Investigation IMPORTANCE: Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic cancer. Its early detection is advisable because 20% of women have advanced disease at the time of diagnosis. OBJECTIVE: To clinically validate a metabolomics-based classification algorithm as a screening test for EC. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study enrolled 2 cohorts. A multicenter prospective cohort, with 50 cases (postmenopausal women with EC; International Federation of Gynecology and Obstetrics stage I-III and grade G1-G3) and 70 controls (no EC but matched on age, years from menopause, tobacco use, and comorbidities), was used to train multiple classification models. The accuracy of each trained model was then used as a statistical weight to produce an ensemble machine learning algorithm for testing, which was validated with a subsequent prospective cohort of 1430 postmenopausal women. The study was conducted at the San Giovanni di Dio e Ruggi d’Aragona University Hospital of Salerno (Italy) and Lega Italiana per la Lotta contro i Tumori clinic in Avellino (Italy). Data collection was conducted from January 2018 to February 2019, and analysis was conducted from January to March 2019. MAIN OUTCOMES AND MEASURES: The presence or absence of EC based on evaluation of the blood metabolome. Metabolites were extracted from dried blood samples from all participants and analyzed by gas chromatography–mass spectrometry. A confusion matrix was used to summarize test results. Performance indices included sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios, and accuracy. Confirmation or exclusion of EC in women with a positive test result was by means of hysteroscopy. Participants with negative results were followed up 1 year after enrollment to investigate the appearance of EC signs. RESULTS: The study population consisted of 1550 postmenopausal women. The mean (SD) age was 68.2 (11.7) years for participants with no EC in the training cohort, 69.4 (13.8) years for women with EC in the training cohort, and 59.7 (7.7) years for women in the validation cohort. Application of the ensemble machine learning to the validation cohort resulted in 16 true-positives, 2 false-positives, and 0 false-negatives, and it correctly classified more than 99% of samples. Disease prevalence was 1.12% (16 of 1430). CONCLUSIONS AND RELEVANCE: In this study, dried blood metabolomic profile was used to assess the presence or absence of EC in postmenopausal women not receiving hormonal therapy with greater than 99% accuracy. American Medical Association 2020-09-28 /pmc/articles/PMC7522698/ /pubmed/32986110 http://dx.doi.org/10.1001/jamanetworkopen.2020.18327 Text en Copyright 2020 Troisi J et al. JAMA Network Open. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Troisi, Jacopo
Raffone, Antonio
Travaglino, Antonio
Belli, Gaetano
Belli, Carmen
Anand, Santosh
Giugliano, Luigi
Cavallo, Pierpaolo
Scala, Giovanni
Symes, Steven
Richards, Sean
Adair, David
Fasano, Alessio
Bottigliero, Vincenzo
Guida, Maurizio
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
title Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
title_full Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
title_fullStr Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
title_full_unstemmed Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
title_short Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women
title_sort development and validation of a serum metabolomic signature for endometrial cancer screening in postmenopausal women
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522698/
https://www.ncbi.nlm.nih.gov/pubmed/32986110
http://dx.doi.org/10.1001/jamanetworkopen.2020.18327
work_keys_str_mv AT troisijacopo developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT raffoneantonio developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT travaglinoantonio developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT belligaetano developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT bellicarmen developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT anandsantosh developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT giuglianoluigi developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT cavallopierpaolo developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT scalagiovanni developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT symessteven developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT richardssean developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT adairdavid developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT fasanoalessio developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT bottiglierovincenzo developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen
AT guidamaurizio developmentandvalidationofaserummetabolomicsignatureforendometrialcancerscreeninginpostmenopausalwomen